PPAR-γ ligand promotes the growth of APC-mutated HT-29 human colon cancer cells in vitro and in vivo.
- Published in:
- Investigational New Drugs, 2008, v. 26, n. 3, p. 283, doi. 10.1007/s10637-007-9108-x
- By:
- Publication type:
- Article
Works matching IS 01676997 AND DT 2008 AND VI 26 AND IP 3
Results: 12
1
2
A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas.
- Published in:
- Investigational New Drugs, 2008, v. 26, n. 3, p. 241, doi. 10.1007/s10637-008-9118-3
- By:
- Publication type:
- Article
3
Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma.
- Published in:
- Investigational New Drugs, 2008, v. 26, n. 3, p. 273, doi. 10.1007/s10637-007-9107-y
- By:
- Publication type:
- Article
4
Extrinsic nitric oxide donor partially reverses arginine deiminase induced cell growth inhibition through NFκB and Bcl-X<sub>L</sub>.
- Published in:
- Investigational New Drugs, 2008, v. 26, n. 3, p. 277, doi. 10.1007/s10637-007-9105-0
- By:
- Publication type:
- Article
5
A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168)
- Published in:
- Investigational New Drugs, 2008, v. 26, n. 3, p. 265, doi. 10.1007/s10637-007-9103-2
- By:
- Publication type:
- Article
6
Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck.
- Published in:
- Investigational New Drugs, 2008, v. 26, n. 3, p. 257, doi. 10.1007/s10637-007-9098-8
- By:
- Publication type:
- Article
7
Correlations of mRNA expression and in vitro chemosensitivity to enzastaurin in freshly explanted human tumor cells.
- Published in:
- Investigational New Drugs, 2008, v. 26, n. 3, p. 215, doi. 10.1007/s10637-007-9095-y
- By:
- Publication type:
- Article
8
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.
- Published in:
- Investigational New Drugs, 2008, v. 26, n. 3, p. 233, doi. 10.1007/s10637-008-9115-6
- By:
- Publication type:
- Article
9
A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial.
- Published in:
- Investigational New Drugs, 2008, v. 26, n. 3, p. 249, doi. 10.1007/s10637-007-9097-9
- By:
- Publication type:
- Article
10
Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan.
- Published in:
- Investigational New Drugs, 2008, v. 26, n. 3, p. 205, doi. 10.1007/s10637-007-9093-0
- By:
- Publication type:
- Article
11
The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro.
- Published in:
- Investigational New Drugs, 2008, v. 26, n. 3, p. 195, doi. 10.1007/s10637-007-9092-1
- By:
- Publication type:
- Article
12
A novel quinoline, MT477: suppresses cell signaling through Ras molecular pathway, inhibits PKC activity, and demonstrates in vivo anti-tumor activity against human carcinoma cell lines.
- Published in:
- Investigational New Drugs, 2008, v. 26, n. 3, p. 223
- By:
- Publication type:
- Article